Development

Image

AVA NewTechnology

Highest specificity with AVA-NextGenMonoclonals™

AVA LifeScience develops effective strategies for targeted therapies based on highly specific antibodies. The precise identification of tumor-specific structures using NextGenMonoclonals™ enables targeted therapy.
Image

AVA DiagnostiX

Highest efficiency through immune profiling

AVA LifeScience develops ApLife™, the new gold standard for flow cytometric diagnostics of leukemias and lymphomas based on NextGenMonoclonals™.
Image

AVA TherapeutiX

Highest efficiency through precision

We develop new strategies for targeted therapies and personalized medication with our pinpoint NextGenMonoclonals™.

News